McMahon K Wyatt, Karunasena Enusha, Ahuja Nita
From the Departments of *Surgery, †Oncology, ‡Cancer Immunology, and §Urology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD.
Cancer J. 2017 Sep/Oct;23(5):257-261. doi: 10.1097/PPO.0000000000000279.
Next year will mark 60 years since Dr. Leslie Foulds outlined his hypothesis that cancer is "a dynamic process advancing through stages that are qualitatively different," leading the way to our view of cancer progression as we know it today. Our understanding of the mechanisms of these stages has been continuously evolving this past half-century, and there has always been an active discussion of the roles of both genetic and epigenetic changes in directing this progression. In this review, we focus on the roles one particular epigenetic mark-DNA methylation-plays in these various "discontinuous" stages of cancer. Understanding these steps not only gives us a better picture of how this fascinating biological process operates, but also opens the doors to new prognostic biomarkers and therapies against these malignancies.
明年将迎来莱斯利·福尔兹博士提出其假说60周年。该假说认为癌症是“一个通过性质不同的阶段不断发展的动态过程”,为我们如今所知的癌症进展观点奠定了基础。在过去的半个世纪里,我们对这些阶段机制的理解一直在不断发展,并且对于基因和表观遗传变化在引导这一进展过程中的作用一直存在着积极的讨论。在这篇综述中,我们聚焦于一种特定的表观遗传标记——DNA甲基化——在癌症这些不同的“不连续”阶段中所起的作用。了解这些步骤不仅能让我们更好地了解这个迷人的生物学过程是如何运作的,还为针对这些恶性肿瘤的新的预后生物标志物和治疗方法打开了大门。